Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Benzinga

08/06

Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.

“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.

Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.

These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.

RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.
B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.

Considering buying AXSM stock? Here’s what analysts think:

Read This Next:

Top 2 Financial Stocks That May Collapse This Month

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557315445"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557315445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557315445?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 01:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557315445","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>, Inc</strong>. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.</p>\n<p>Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.</p>\n<p>“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.</p>\n<p>Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.</p>\n<ul>\n<li>RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.</li>\n</ul>\n<p><strong>Considering buying AXSM stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"601\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72.png 1145w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Financial Stocks That May Collapse This Month</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-08-06 01:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>, Inc</strong>. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.</p>\n<p>Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.</p>\n<p>“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.</p>\n<p>Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.</p>\n<ul>\n<li>RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.</li>\n</ul>\n<p><strong>Considering buying AXSM stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"601\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72.png 1145w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Financial Stocks That May Collapse This Month</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46866768/axsome-therapeutics-analysts-increase-their-forecasts-after-q2-earnings","article_id":"2557315445","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557315445","pubTimestamp":1754415651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics分析师在第二季度财报公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1},"content_text":"Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.\nAxsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.\n“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.\nAxsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.\nThese analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.\n\nRBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.\nB of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.\n\nConsidering buying AXSM stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Financial Stocks That May Collapse This Month\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}